

MIR133A regulate SOX9 in colorectal cancer

Table S1. Primer sequences used for MIR133A knock-in, qRT-PCR, luciferase assay and Taq-Man analysis in this study

Applications	Primers*	Primer sequence (5'→3')
Knock-In	MIR133A1-F	CACGGATCCCTAGCAGCACTACAATGC
	MIR133A1-R	CCGAAGCTTGTCCCGTAGTAATCAATGCATA
	MIR133A2-F	TATGGATCCTCCGACGTCGCTGTTC
	MIR133A2-R	TATAAGCTTCACGGCTGCGGGACCT
qRT-PCR	SOX9-QF1	CGAAGATGGCCGAGATGATCC
	SOX9-QR1	GGATAGGTCATGTTTGTGTCTTGG
	GAPDH-F	CAATGACCCCTTCATTGACC
	GAPDH-R	GACAAAGCTTCCCGTTCTCAG
Luciferase assay	SOX9-WF	CGACGAGCTCCTCACCTACATGAACC
	SOX9-WR	GCTGCTCGAGGTTGCCTTTAGCTTAAATGTC
	SOX9-MF	CCGAAGAAAGAGACCAGAATTCCTTTGG
	SOX9-MR	CCAAAGGAATTCTGGTCTCTTTCTTCGG
Taq-Man analysis	Hsa-mir-133A	ID: PM10413 (Applied Biosystems)
	RNU48	GATGACCCAGGTAAGTCTGAGTGTGTCGC TGATGCCATCACCGCAGCGCTCTGACC

*QF: quantitative forward primer; QR: quantitative reverse primer; WF: forward primer for wild-type constructs; WR: reverse primer for wild-type constructs; MF: forward primer for mutate-type constructs; MR: reverse primer for mutate-type constructs.




Figure S1. SOX9 mRNA and protein levels and MIR133A1 and A2 KI cell lines. A. qRT-PCR analysis of SOX9 mRNA expression in MIR133A1 and A2 KI SW48 cells relative to mock cells. B. Western blot analysis of SOX9 in MIR133A1 and A2 KI SW48 and HCT116 cells. Differences were considered statistically significant * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ compared with control.

MIR133A regulate SOX9 in colorectal cancer




Figure S2. Cell proliferation in MIR133A1 and A2 KI cell lines. MTT assays of mock and MIR133A1 and A2. Representative data from at least three independent experiments are shown. Each bar represents mean fold alteration above or below control (\pm SD). Differences were considered statistically significant ** $P < 0.01$, *** $P < 0.001$ compared with control (ns = not significant).